Eli Lilly nabs CoLucid and a PhIII migraine drug in $960M buyout
Eli Lilly’s new CEO has pulled off his first M&A deal.
The pharma giant $LLY is buying CoLucid $CLCD for $960 million, adding some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
